<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="195"><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60684"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="307614"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="203343"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="91153"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Sponsor>Path Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="269874"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>HVT</ProtocolAcronym><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Sponsor>McMaster University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="265194"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="233238"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60050"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11389"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11387"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="9965"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60684"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="17509"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Determine If Upper Respiratory Tract Infection (URI) Affects The Seroconversion Rate Or Quantitative Response To Each Component Of ProQuad</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15334"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15301"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of ProQuad rHA in Infants</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11426"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I Study of MVA-BN Vector Vaccine to Evaluate Safety and Immunogenicity in Healthy Volunteers</ProtocolTitle><Sponsor>Bavarian Nordic A/S</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Status not specified</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="9026"></Trial><Drug id="54328">MVA-mBN85B</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="198691"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (phase III)</ProtocolTitle><Sponsor>POLYVAC</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="357452"></Trial><Drug id="113162">MRVAC</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11526"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and safety of GSK Biologicals malaria vaccine given at 6,7.5 and 9 months of age coadministered with measles,rubella and yellow fever vaccines</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="261663"></Trial><Drug id="14289">malaria vaccine, GlaxoSmithKline/Malaria Vaccine Initiative</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="124248"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunological Effect of Early Extra MMR Immunization in Infants Between 6 and 12 Months of Age in an Outbreak Setting</ProtocolTitle><Sponsor>National Institute for Public Health and the Environment</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="156178"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11526"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9949"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11423"></Trial><Drug id="14438">Avaxim</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88475"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="77052"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Measles, Mumps, and Rubella (MMR) Immunity in College Students</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="59758"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60050"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Sponsor>Themis Bioscience GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="268409"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative Study To Evaluate The Efficacy Of Priorix With ROR Vax</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15245"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11418"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88475"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11526"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years</ProtocolTitle><Sponsor>Bavarian Nordic A/S</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="59936"></Trial><Drug id="54328">MVA-mBN85B</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>BIOMR</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="298150"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III clinical trial of JVC-001 for the prevention of measles, mumps and rubella infection</ProtocolTitle><Sponsor>Japan Vaccine Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Planned</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="350532"></Trial><Drug id="99518">JVC-001</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-blind, randomized trial to evaluate the safety and immunogenicity of JVC-001 intended for Japanese healthy children</ProtocolTitle><Sponsor>Japan Vaccine Co Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Trial id="244020"></Trial><Drug id="99518">JVC-001</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15250"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10810"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="94105"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77052"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="44865"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15335"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10223"></Trial><Drug id="15298">Pentacel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77052"></Trial><Drug id="30214">diphtheria/tetanus/pertussis vaccine, sanofi pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="83852"></Trial><Drug id="10593">Meningitec</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85664"></Trial><Drug id="56585">Vaxelis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="9967"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44865"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="17509"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15317"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative Study To Evaluate The Efficacy Of Priorix With ROR Vax</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15245"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11384"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Sponsor>Health Protection Agency</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="132011"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="102759"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="10223"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="102759"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-term Follow-up of Measles Antibodies</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="14946"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="85664"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="161697"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study To Compare The Immune Response And Safety Of Measles Vaccine Manufactured By Cadila Healthcare Ltd, With Measles Vaccine Manufactured By Serum Institute Of India Ltd, In Children 9 to 12 Months Of Age</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="229988"></Trial><Drug id="97346">measles vaccine, Cadila Healthcare</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Trial id="206205"></Trial><Drug id="99042">double viral vaccine (measles/rubella), Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60653"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Sponsor>Health Protection Agency</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132011"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77052"></Trial><Drug id="49241">Quadracel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Of Prophylactic Antibiotics in Measles</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11380"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233238"></Trial><Drug id="42065">Bexsero</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="203343"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10223"></Trial><Drug id="84867">Vaxem HIB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="77052"></Trial><Drug id="44408">polio vaccine, Sanofi Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60653"></Trial><Drug id="10530">Comvax</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15301"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>BREMEAVAC</ProtocolAcronym><ProtocolTitle>Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire de Limoges</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="218981"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="172270"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15250"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11425"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MEMURU-OKA-049</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GSK Biologicals 208136 Vaccine Formulated With New Measles and Rubella Working Seeds</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="54026"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparative, Randomized, Phase III Study To Evaluate the Immunogenicity Of Priorix-Tetra With Priorix And Varilrix In Healthy Children</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15250"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Sponsor>Crucell Switzerland AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="17279"></Trial><Drug id="41069">second-generation MMR vaccine, Berna</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="184151"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15333"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ProQuad Intramuscular versus Subcutaneous</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11634"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11511"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="124248"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase-I study to evaluate the safety and tolerability of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children in a single-dose schedule</ProtocolTitle><Sponsor>Biological E Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="246741"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to evaluate the safety and immunogenicity of HBI Measles and Rubella vaccine (Live) in two age groups of healthy male subjects</ProtocolTitle><Sponsor>Indian Immunologicals Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="377732"></Trial><Drug id="115970">live-attenuated viral vaccine (sc, measles/rubella virus infection), Indian Immunologicals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="124248"></Trial><Drug id="22877">RotaTeq</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15317"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11525"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11515"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="203343"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Sponsor>Path Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="269874"></Trial><Drug id="60890">SA-14-14-2</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the immunogenicity and safety of Japanese encephalitis vaccine when given with measles-mumps-rubella vaccine</ProtocolTitle><Sponsor>Path Inc, Syneos Health Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="268796"></Trial><Drug id="60890">SA-14-14-2</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10599"></Trial><Drug id="17821">Infanrix HeXa</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85664"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>HVT</ProtocolAcronym><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Sponsor>McMaster University</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="265194"></Trial><Drug id="47199">Adacel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="94105"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="91153"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="79465"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="172270"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="79465"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase IV, Open, Multicentric, Post-marketing Surveillance Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals Live Attenuated Measles-Mumps-Rubella vaccine (Priorix) in Korean Subjects Administered According to the Prescribing Information</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="172850"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="9859"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11963"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="102759"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233238"></Trial><Drug id="17674">Infanrix Quinta</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="79465"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, multicenter comparative study to evaluate the safety and immunogenicity Of ProQuad when administered in combination with other vaccines against Varivax and MMR II when co-administered with the same vaccines</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="17509"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15243"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9859"></Trial><Drug id="55366">Nimenrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="124248"></Trial><Drug id="55366">Nimenrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85664"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10223"></Trial><Drug id="39031">Menveo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9859"></Trial><Drug id="10593">Meningitec</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9965"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15335"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15333"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15243"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="94105"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="161697"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11388"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11388"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>6</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="60653"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to evaluate frozen versus refrigerated MMRV (combined Measles, Mumps, Rubella, and Varicella) investigational vaccine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="12456"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11515"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="10599"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="85837"></Trial><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine</ProtocolTitle><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="298801"></Trial><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>MMR at 6 Months Trial</ProtocolTitle><Sponsor>Danish National University Hospital, Rigshospitalet, Denmark</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="364134"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR</ProtocolAcronym><ProtocolTitle>Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single- Dose and Multidose Presentations</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Trial id="106360"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Post Licensure Clinical Trial to Assess the Safety and Tolerability of BEs Measles-rubella Vaccine in 9 to 12 Months Old Healthy Infants in a Single-Dose</ProtocolTitle><Sponsor>Biological E Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="378426"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Assess the Safety and Tolerability of Measles, Mumps, Rubella and Varicella Vaccine (Live-Attenuated, Freeze-Dried) in Healthy Adult Male Human Subjects</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Trial id="243853"></Trial><Drug id="97994">MMRV vaccine, Zydus Cadila Healthcare</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="187831"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11418"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Vyriad</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="273428"></Trial><Drug id="101326">MV-NIS (lung cancer), Vyriad</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="91153"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="203343"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of a Refrigerator-Stable Formulation of Varivax</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11524"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="94105"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="88475"></Trial><Drug id="57017">Kinrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10810"></Trial><Drug id="7080">Pneumovax 23</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="340960"></Trial><Drug id="102979">quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="91153"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9967"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="9949"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="184151"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Sponsor>Crucell Switzerland AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="17279"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11525"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="187831"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11526"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11418"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="44865"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Compare The Bioequivalence Of Proquad With Standard MMR And Varicella Vaccines</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15335"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants</ProtocolTitle><Sponsor>Queen Sirikit National Institute of Child Health</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="104131"></Trial><Drug id="83793">Trivivac</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to assess the safety and protective efficacy of Biological Es Measles-Rubella Vaccine in 9 to 12 months old Infants in India</ProtocolTitle><Sponsor>Biological E Ltd</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="266205"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11388"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="10223"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="340960"></Trial><Drug id="59852">Pentaxim</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="307614"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-blind, Multicenter Study To Evaluate The Safety, Tolerability And Immunogenicity Of ProQuad For The Prevention Of Measles, Mumps, Rubella And Chicken Pox In Children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15301"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233238"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="124248"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="124248"></Trial><Drug id="56585">Vaxelis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Sponsor>Health Protection Agency</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="132011"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11515"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="88475"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="203343"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy,Bioequivalence</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Compare The Safety, Immunogenicity, and Consistency Of Three Production Lots Of Priorix With MMR II Vaccine</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15243"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="83852"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="187831"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of ProQuad in Children 6 to 24 Months Being Evaluated for Solid Organ Transplant</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="254035"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Multicenter Comparative Study To Evaluate The Safety And Immunogenicity Of ProQuad With MMR II Plus Varivax</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="15317"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of Immunogenicity and Safety of a two-dose Regimen of ProQuad Manufactured With rHA</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp, Sanofi Pasteur MSD</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="11632"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Trial id="200688"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym>BMR-3</ProtocolAcronym><ProtocolTitle>Third MMR Vaccine Dose In Young Adults</ProtocolTitle><Sponsor>National Institute for Public Health and the Environment</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Not yet recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Trial id="270107"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="60050"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2+</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9965"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="79465"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="340960"></Trial><Drug id="22877">RotaTeq</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Evaluate The Safety And Immunogenicity of a combined live attenuated measles, mumps, rubella and varicella vaccine, ProQuad In Healthy Children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="15333"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="NS">Phase not specified</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9967"></Trial><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>4+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="9949"></Trial><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="91153"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="340960"></Trial><Drug id="39031">Menveo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>2</ArmCount><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="11511"></Trial><Drug id="3263">Vaqta</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Sponsor>Themis Bioscience GmbH</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="268409"></Trial><Drug id="75100">MV-CHIK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85664"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="85664"></Trial><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>5</ArmCount><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="94105"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>3+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Completed</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="79465"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Vyriad</Sponsor><StudyType>Interventional</StudyType><TrialStatus>Terminated</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="273428"></Trial><Drug id="72699">atezolizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233238"></Trial><Drug id="12813">Rotarix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row><Row><Ancestry></Ancestry><ArmCount>1+</ArmCount><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><StudyType>Interventional</StudyType><TrialStatus>No longer recruiting</TrialStatus><Indication id="1">Measles virus infection</Indication><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Trial id="233238"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>